1. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma 
Carlos Iribarren, MD, MPH, PhD, Abdelkader Rahmaoui, MD, Aidan A. Long, MD, Stanley J. Szefler, MD, Mary S. Bradley, MS, Gillis Carrigan, PhD, MSc, Mark D. Eisner, MD, MPH, Hubert Chen, MD, MPH, Theodore A. Omachi, MD, MBA, Michael E. Farkouh, MD, MSc, Kenneth J. Rothman, DrPH 
Journal of Allergy and Clinical Immunology 
Volume 139, Issue 5, Pages e5 (May 2017)
DOI: /j.jaci
Copyright © 2016 The Authors Terms and Conditions

2. Fig 1
Identification and adjudication of CV and CBV events. MedDRA, Medical Dictionary for Regulatory Activities; SMQ, Standardized Medical Dictionary for Regulatory Activities Query.
Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci )
Copyright © 2016 The Authors Terms and Conditions

3. Fig 2
Kaplan-Meier plot of time to first adjudicated study-emergent ATE SAE.
Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci )
Copyright © 2016 The Authors Terms and Conditions

4. Fig E1
Patient use of OCSs during EXCELS, by treatment cohort and asthma severity. BL, Baseline.
Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci )
Copyright © 2016 The Authors Terms and Conditions